The prominent role of EGFR signaling in colon cancer cell [16] and its ability to modulate key hallmarks of cancer progression [117,118] has already stimulated the development of several anti-EGFR monoclonal antibodies and receptor tyrosine kinase inhibitors [118,119,120]. This evidence concerns the gene EGFR and malignant colon neoplasm.